Overview

Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia

Status:
Terminated
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether epratuzumab provides effective therapy in Waldenström's Macroglobulinemia (WM).
Phase:
Phase 2
Details
Lead Sponsor:
Gilead Sciences
Immunomedics, Inc.
Treatments:
Antibodies
Epratuzumab
Immunoglobulins